3 Maggio 2019

EU Panel Recommends Revoking Olaratumab in Soft Tissue Sarcoma

April 29, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the conditional marketing authorization for olaratumab be revoked following results of the ANNOUNCE study, which did not demonstrate a survival benefit with the PDGFRα antagonist in combination with doxorubicin versus doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma (STS). The CHMP made … (leggi tutto)